BRPI0716815A2 - Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) - Google Patents
Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p)Info
- Publication number
- BRPI0716815A2 BRPI0716815A2 BRPI0716815-2A2A BRPI0716815A BRPI0716815A2 BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2 BR PI0716815 A BRPI0716815 A BR PI0716815A BR PI0716815 A2 BRPI0716815 A2 BR PI0716815A2
- Authority
- BR
- Brazil
- Prior art keywords
- spinphosine
- heteroatomatic
- agonist
- phosphate
- receiver
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000004071 biological effect Effects 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82480706P | 2006-09-07 | 2006-09-07 | |
| PCT/US2007/077588 WO2008030843A1 (en) | 2006-09-07 | 2007-09-05 | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0716815A2 true BRPI0716815A2 (pt) | 2013-11-05 |
Family
ID=38961939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716815-2A2A BRPI0716815A2 (pt) | 2006-09-07 | 2007-09-05 | Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2066633A1 (OSRAM) |
| JP (1) | JP2010504286A (OSRAM) |
| AU (1) | AU2007292347A1 (OSRAM) |
| BR (1) | BRPI0716815A2 (OSRAM) |
| CA (1) | CA2662852A1 (OSRAM) |
| WO (1) | WO2008030843A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005014271A1 (de) * | 2005-03-24 | 2006-09-28 | Rhein Chemie Rheinau Gmbh | Mikrogele in Kombination mit funktionalen Additiven |
| US8563594B2 (en) | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
| KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| AU2009288738B9 (en) | 2008-08-27 | 2015-04-16 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| KR20120098796A (ko) | 2009-11-24 | 2012-09-05 | 알러간, 인코포레이티드 | 치료적 유용성을 지니는 수용체 조절제로서의 신규한 화합물 |
| US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
| CA2799015A1 (en) | 2010-05-14 | 2011-11-17 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
| US8513220B2 (en) | 2010-05-14 | 2013-08-20 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity |
| JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用 |
| MX2016007522A (es) | 2013-12-11 | 2017-12-15 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| KR102859841B1 (ko) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH06501926A (ja) * | 1990-08-06 | 1994-03-03 | 藤沢薬品工業株式会社 | 複素環式化合物 |
| WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
-
2007
- 2007-09-05 BR BRPI0716815-2A2A patent/BRPI0716815A2/pt not_active IP Right Cessation
- 2007-09-05 EP EP07841853A patent/EP2066633A1/en not_active Withdrawn
- 2007-09-05 WO PCT/US2007/077588 patent/WO2008030843A1/en not_active Ceased
- 2007-09-05 CA CA002662852A patent/CA2662852A1/en not_active Abandoned
- 2007-09-05 AU AU2007292347A patent/AU2007292347A1/en not_active Abandoned
- 2007-09-05 JP JP2009527532A patent/JP2010504286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2662852A1 (en) | 2008-03-13 |
| AU2007292347A1 (en) | 2008-03-13 |
| WO2008030843A1 (en) | 2008-03-13 |
| JP2010504286A (ja) | 2010-02-12 |
| EP2066633A1 (en) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0716815A2 (pt) | Co posto heteroatomáticos tendo atividade biológia agonista e/ou antagonista de receptor de esfinfosina-1-fosfato (s1p) | |
| BRPI0813580A2 (pt) | Antagonistas de receptor 1 de hormônio de concentração de melanina não básicos e métodos | |
| LTPA2021502I1 (lt) | Angiotenzino receptorių antagonisto ir NEP inhibitoriaus farmaciniai deriniai | |
| BRPI1014877A8 (pt) | compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor b2 adrenérgico. | |
| BRPI0815668A2 (pt) | compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato. | |
| BRPI0719184A2 (pt) | Análise e gerenciamento de sistema | |
| BRPI0818216A2 (pt) | derivado de amina tendo atividade antagonista do receptor npy y5 e uso do mesmo | |
| EP2083859A4 (en) | PCSK9 ANTAGONISTS | |
| EP2083860A4 (en) | PCSK9 ANTAGONISTS | |
| PT1857457E (pt) | Derivado de benzimidazole e sua utilização como antagonista do receptor a ii | |
| EP2004654A4 (en) | Kinase Antagonists | |
| EP1968583A4 (en) | COMPOUNDS, SCREENING AND TREATMENT PROCEDURES | |
| BRPI0720124A2 (pt) | Composições farmacêuticas e seus métodos de uso. | |
| DK2049478T3 (da) | Substituerede N-phenylmethyl-5-oxoprolin-2-amider som P2X7-receptorantagonister og fremgangsmåder til anvendelse deraf | |
| DK1615889T3 (da) | Biphenylderivater med beta2-adrenergisk receptoragonist- og muscarinisk receptorantagonistaktivitet | |
| EP1824516A4 (en) | GLYCAN ANALYSIS WITH DEUTERATED GLUCOSE | |
| EP1957498A4 (en) | VEGF AND HGF RECEPTOR SIGNALING INHIBITORS | |
| EP1948680A4 (en) | METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS | |
| EP1718662A4 (en) | Multiplex detection probes | |
| EP1765805A4 (en) | CGRP RECEPTOR ANTAGONISTS | |
| BRPI0806966A2 (pt) | Combinação de um antagonista de receptor muscarínico e um agonista beta-2-adrenoceptor | |
| EP1799672A4 (en) | CGRP RECEPTOR ANTAGONIST | |
| GB0611154D0 (en) | Novel receptor antagonists and their methods of use | |
| EP2150248A4 (en) | GLUTAMATE RECEPTOR ANTAGONISTS AND METHOD OF USE | |
| DE602005009355D1 (de) | Gehinderte himbacinanaloga als thrombinrezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08L | Application fees: final archiving |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES. |
|
| B08I | Application fees: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |